褪黑素治疗创伤性脑损伤患者睡眠障碍及情绪障碍的临床效果

doi:10.20047/j.issn1673-7210.2022.26.17

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (500 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察褪黑素治疗创伤性脑损伤患者睡眠障碍及情绪障碍的临床效果。方法选取2019年8月至2021年8月在重庆医科大学附属第一医院神经外科接受治疗的轻中型创伤性脑损伤患者27例，采用随机数字表法将其分为褪黑素组（13例）和对照组（14例）。褪黑素组每晚入睡前30 min口服褪黑素胶囊，对照组每晚入睡前30 min口服安慰剂，两组均持续用药4周。治疗后，采用匹兹堡睡眠质量指数（PSQI）、Epworth嗜睡量表（ESS）、医院焦虑抑郁量表（HADS）和扩展版格拉斯哥结局量表（GOS-E）评价两组睡眠障碍、情绪障碍及功能结局情况。记录两组服药期间不良反应发生情况。结果治疗后，褪黑素组PSQI、ESS和HADS焦虑评分均低于对照组，差异有统计学意义（P ＜ 0.05）。两组HADS抑郁评分和GOS-E评分比较，差异无统计学意义（P ＞ 0.05）。两组乏力、嗜睡、头痛、头晕、恶心呕吐发生率比较，差异均无统计学意义（P ＞ 0.05）。结论褪黑素能改善创伤性脑损伤后的睡眠障碍并缓解焦虑情绪，安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴晨瑞吴碧莹付嘉园圆谭伟霖周强杜梦然黄雪康廖正步

关键词 ：褪黑素, 创伤性脑损伤, 睡眠障碍, 情绪障碍

Abstract：Objective To observe the clinical efficacy of Melatonin on sleep disorder and mood disorder in patients with traumatic brain injury. Methods A total of 27 patients with mild to moderate traumatic brain injury treated in the Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University from August 2019 to August 2021 were selected and divided into Melatonin group (13 cases) and control group (14 cases) by random number table method. The Melatonin group took Melatonin Capsules orally 30 minutes before falling asleep every night, while the control group took placebo orally 30 minutes before falling asleep every night. Both groups continued to take the drug for four weeks. After treatment, Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale (ESS), hospital anxiety and depression scale (HADS), and Glasgow outcome scale-extended (GOS-E) were used to evaluate sleep disorder, mood disorder, and functional outcomes in the two groups. The incidence of adverse reactions during medication was recorded in both groups. Results After treatment, the PSQI, ESS, and HADS anxiety scores of Melatonin group were lower than those of control group, and the differences were statistically significant (P ＜ 0.05). There was no significant difference in HADS depression score and GOS-E score between the two groups (P ＞ 0.05). There was no significant difference in the incidence of fatigue, drowsiness, headache, dizziness, nausea, and vomiting between the two groups (P ＞ 0.05). Conclusion Melatonin can improve sleep disturbance and relieve anxiety after traumatic brain injury, with good safety.

Key words： Melatonin Traumatic brain injury Sleep disorder Mood disorder

基金资助:国家自然科学基金面上项目（81771355）。

通讯作者: 廖正步（1975.9-），男，博士，副教授，硕士生导师；研究方向：颅脑损伤的治疗与神经功能修复。

引用本文:

吴晨瑞吴碧莹付嘉园圆谭伟霖周强杜梦然黄雪康廖正步. 褪黑素治疗创伤性脑损伤患者睡眠障碍及情绪障碍的临床效果[J]. 中国医药导报, 2022, 19(26): 75-78.
WU Chenrui WU Biying FUJiayuanyuan TAN Weilin ZHOU Qiang DU Mengran HUANG Xuekang LIAO Zhengbu. Clinical efficacy of Melatonin on sleep disorder and mood disorder in patients with traumatic brain injury. 中国医药导报, 2022, 19(26): 75-78.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2022.26.17 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I26/75

[1] Mathias JL，Alvaro PK. Prevalence of sleep disturbances，disorders，and problems following traumatic brain injury：a meta-analysis [J]. Sleep Med，2012，13（7）：898-905.
[2] Ouellet MC，Beaulieu-Bonneau S，Morin CM. Sleep-wake disturbances after traumatic brain injury [J]. Lancet Neurol，2015，14（7）：746-757.
[3] Imbach LL，Büchele F，Valko PO，et al. Sleep-wake disorders persist 18 months after traumatic brain injury but remain underrecognized [J]. Neurology，2016，86（21）：1945-1949.
[4] Mahmood O，Rapport LJ，Hanks RA，et al. Neuropsychological performance and sleep disturbance following traumatic brain injury [J]. J Head Trauma Rehabil，2004，19（5）：378-390.
[5] Nakase-Richardson R，Sherer M，Barnett SD，et al. Prospective evaluation of the nature，course，and impact of acute sleep abnormality after traumatic brain injury [J]. Arch Phys Med Rehabil，2013，94（5）：875-882.
[6] Shekleton JA，Parcell DL，Redman JR，et al. Sleep disturbance and melatonin levels following traumatic brain injury [J]. Neurology，2010，74（21）：1732-1738.
[7] Larrabee GJ，Rohling ML. Neuropsychological differential diagnosis of mild traumatic brain injury [J]. Behav Sci Law，2013，31（6）：686-701.
[8] Buysse DJ，Reynolds CF，Monk TH，et al. The Pittsburgh Sleep Quality Index：a new instrument for psychiatric practice and research [J]. Psychiatry Res，1989，28（2）：193-213.
[9] Johns MW. A new method for measuring daytime sleepiness：the Epworth sleepiness scale [J]. Sleep，1991，14（6）：540-545.
[10] Zigmond AS，Snaith RP. The hospital anxiety and depression scale [J]. Acta Psychiatr Scand，1983，67（6）：361-370.
[11] Wilson JT，Pettigrew LE，Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale：guidelines for their use [J]. J Neurotrauma，1998，15（8）：573-585.
[12] Osier N，McGreevy E，Pham L，et al. Melatonin as a Therapy for Traumatic Brain Injury：A Review of Published Evidence [J]. Int J Mol Sci，2018，19（5）：1539.
[13] Grima NA，Rajaratnam S，Mansfield D，et al. Efficacy of melatonin for sleep disturbance following traumatic brain injury：a randomised controlled trial [J]. BMC Med，2018，16（1）：8.
[14] Grima NA，Rajaratnam S，Mansfield D，et al. Poorer sleep quality predicts melatonin response in patients with traumatic brain injury：findings from a randomized controlled trial [J]. J Clin Sleep Med，2021，17（8）：1545-1551.
[15] Wu C，Du M，Yu R，et al. A novel mechanism linking ferroptosis and endoplasmic reticulum stress via the circPtpn14/miR-351-5p/5-LOX signaling in melatonin-mediated treatment of traumatic brain injury [J]. Free Radic Biol Med，2022，178：271-294.
[16] Golombek DA，Martini M，Cardinali DP. Melatonin as an anxiolytic in rats：time dependence and interaction with the central GABAergic system [J]. Eur J Pharmacol，1993，237（2/3）：231-236.
[17] Pierrefiche G，Zerbib R，Laborit H. Anxiolytic activity of melatonin in mice：involvement of benzodiazepine receptors [J]. Res Commun Chem Pathol Pharmacol，1993，82（2）：131-142.
[18] Marseglia L，D’Angelo G，Manti S，et al. Analgesic，anxiolytic and anaesthetic effects of melatonin：new potential uses in pediatrics [J]. Int J Mol Sci，2015，16（1）：1209-1220.
[19] Arioz BI，Tastan B，Tarakcioglu E，et al. Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway [J]. Front Immunol，2019，10：1511.
[20] Ali T，Rahman SU，Hao Q，et al. Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation [J]. J Pineal Res，2020，69（2）：e12667.
[21] Madsen MT，Zahid JA，Hansen CH，et al. The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome：The MEDACIS randomized clinical trial [J]. J Psychiatr Res，2019，119：84-94.
[22] Cardinali DP，Srinivasan V，Brzezinski A，et al. Melatonin and its analogs in insomnia and depression [J]. J Pineal Res，2012，52（4）：365-375.
[23] de Bodinat C，Guardiola-Lemaitre B，Moca?觕r E，et al. Agomelatine，the first melatonergic antidepressant：discovery，characterization and development [J]. Nat Rev Drug Discov，2010，9（8）：628-642.
[24] Rehman SU，Ikram M，Ullah N，et al. Neurological Enhancement Effects of Melatonin against Brain Injury-Induced Oxidative Stress，Neuroinflammation，and Neurodegeneration via AMPK/CREB Signaling [J]. Cells，2019， 8（7）：760.
[25] Weishaupt JH，Bartels C，P?觟lking E，et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment [J]. J Pineal Res，2006，41（4）：313-323.